COVID-19 Mucosal Antibody Assay
By developing assays to detect COVID-19 antibodies and administering vaccines to mucosal tissues, the methods enhance diagnostic efficiency and treatment efficacy, particularly in high-risk populations.
Patent Information
- Application Number
- JP2023503132
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-01-08
- Filing Date
- 2021-06-03
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2041-06-03
AI Technical Summary
Current diagnostic tests for COVID-19 are inefficient, and treatments for the disease have not shown significant success, particularly in high-risk populations, highlighting the need for improved methods to detect immune responses and reduce virus entry and transmission.
The development of assays to detect neutralizing and non-neutralizing antibodies in patient samples, such as saliva and nasal mucosa, using recombinant ACE2 proteins to inhibit SARS-CoV2 spike protein binding, and administering vaccines to mucosal tissues to induce immunity.
The methods allow for accurate detection of immune responses and effective vaccine administration, potentially reducing virus transmission and improving treatment outcomes in high-risk groups.
Smart Images

Figure 0007594083000002 
Figure 0007594083000003 
Figure 0007594083000004
Abstract
Description
[Technical field]
[0001] This application also claims the benefit of priority to U.S. patent applications having serial numbers 63 / 053,691; 63 / 064,157; 63 / 117,460; and 63 / 135,380, each of which is incorporated by reference in its entirety, including any drawings and sequence listings.
[0002] Inclusion of sequence listing This application contains references to nucleic acid and polypeptide sequences filed contemporaneously herewith as a sequence listing text file "PAT.005246.WO001_ST25," created on May 26, 2021. The file is 13 kilobytes in size. The foregoing sequence listing is hereby incorporated by reference in its entirety pursuant to 37 CFR § 1.52(e).
[0003] The present disclosure relates to compositions and methods for assaying viruses or responses to viruses in patient samples, including detecting immunity to viral infection in patient samples, vaccine compositions that target viruses, and administration of vaccines to patients. [Background technology]
[0004] The Background Description includes information that may be useful in understanding the present disclosure. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
[0005] All publications and patent applications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. In the event that a definition or use of a term in an incorporated reference is inconsistent with or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.
[0006] After several notable coronavirus outbreaks in recent years, including SARS and MERS, coronavirus disease 2019 (COVID-19) is yet another example of a severe infectious disease induced by a member of the coronavirus family. Although diagnostic tests have become available in a relatively short time, the tests are not efficient and numerous attempts to treat the disease have not met with significant success so far. Most typically, patients with severe symptoms are treated to maintain breathing / blood oxygenation and supportive care is provided to reduce or prevent multi-organ damage or even failure. Despite such interventions, mortality is significant, especially in the elderly, immunocompromised individuals, and individuals with cardiac disease, pulmonary disease, or diabetes.
[0007] Thus, although various methods for addressing symptoms in patients with COVID-19 are known in the art, all or almost all of them suffer from various drawbacks.Therefore, there is a need to provide improved detection and characterization of a patient's immune response to the virus and / or vaccine compositions, as well as improved compositions and methods that produce an effective immune response to provide a therapeutic effect, reduce or prevent viral entry into cells, reduce direct and indirect toxicity of the virus to the patient, and / or clear the virus from the patient. Summary of the Invention [Means for solving the problem]
[0008] The present disclosure provides methods and compositions for monitoring and assaying viral infection, vaccines, or immune responses to vaccines in patients or patient samples. Contemplated methods include assaying a patient sample for the presence of antibodies against a particular virus. The assay allows for characterization of neutralizing and non-neutralizing antibodies present in the sample, as well as antibody isotypes (e.g., IgA, IgG, or IgE). Exemplary samples from patients include saliva (e.g., oral mucosa), nasal mucosal swabs, and serum samples. Additionally, the methods of the present disclosure include assaying patient samples by competitive inhibition of specific human protein targets of the virus. For example, an assay directed to severe acute respiratory syndrome (SARS)-like coronavirus (SARS-CoV2) activity in a patient may include in vitro detection of neutralizing anti-SARS-CoV2 antibodies that inhibit the SARS-CoV2 spike (S) protein from binding to the human angiotensin-converting enzyme 2 (hACE2) protein, which is the target of the virus.
[0009] The disclosure also includes administering the vaccine composition to a patient by administering the vaccine composition to the patient by delivery to the nasal, oral, and / or gastrointestinal mucosa of the patient. Preferably, the vaccine targets Severe Acute Respiratory Syndrome (SARS)-like coronavirus (SARS-CoV2).
[0010] In particular, the disclosed anti-SARS-CoV2 method includes obtaining a saliva, nasal mucosa, and / or serum sample from a patient at a period of time after administering a vaccine. The sample is first stored in a stabilizing solution comprising glutaraldehyde, sodium benzoate, citric acid, propyl gallate, EDTA, zinc, actin, chitosan, parabens, sodium azide, or any combination thereof. More typically, the stabilizing solution comprises 0.10-2.0% weight / volume (w / v) glutaraldehyde, 0.10-1.0% w / v sodium benzoate, and / or 0.025-0.20% w / v citric acid. Additionally, the stabilizing solution further comprises aragonite particle beads having an average particle size of 100 nm to 1 mm. The aragonite particle beads can bind immunoglobulin (Ig) proteins, anti-SARS-CoV2 antibodies, or SARS-CoV2 viral proteins. In an exemplary embodiment, aragonite particle beads are bound to recombinant ACE2 protein or recombinant ACE2 alpha helix protein.
[0011] In some preferred embodiments, recombinant human ACE2 (rhACE2) protein or peptide is immobilized on a detection surface. A patient sample is incubated with SARS-CoV2 spike (S) protein or peptide (e.g., recombinant SARS-CoV2 spike protein or peptide thereof), and the incubated S protein or peptide and sample are then exposed together to a detection surface with immobilized ACE2 protein or peptide. If the patient sample does not contain any neutralizing anti-SARS-CoV2 antibodies, the receptor binding domain (RBD) of the S protein is available to bind to the ACE2 protein on the detection surface, and the bound S protein is detected using a labeled probe against the S protein. Thus, the presence of neutralizing (e.g., inhibiting) anti-SARS-CoV2 antibodies in the patient sample inhibits the S protein or peptide from binding to ACE2 on the detection surface, thereby preventing detection of the S protein label. Thus, if the label is detected by fluorescence, the increase or presence of fluorescence inversely correlates with the presence of neutralizing anti-SARS-CoV2 antibodies.
[0012] For rapid SARS-CoV2 antibody detection in patient samples, rhACE2 protein or peptides can be immobilized on the surface of aragonite particle beads, or alternatively, on a flat surface suitable for immobilizing protein reagents (e.g., polystyrene multi-well plates). The present disclosure includes kits and methods that use a suitable detection surface (e.g., aragonite particle beads or multi-well plates) pre-bound with rhACE2 protein, peptide, or variants thereof.
[0013] In addition to or instead of wild-type rhACE2 protein or peptide fragments, mutant ACE2 proteins or peptides can be immobilized on the detection surface to further characterize or confirm the binding ability of anti-SARS-CoV2 antibodies found in patient samples. In certain embodiments, the detection surface of an aragonite particle bead or a polystyrene plate is functionalized with a recombinant ACE2 protein having at least 85% sequence identity to SEQ ID NO: 1, a recombinant α-helical ACE2 protein of SEQ ID NO: 2, or a recombinant α-helical ACE2 protein having at least one mutation selected from T27F, T27W, T27Y, D30E, H34E, H34F, H34K, H34M, H34W, H34Y, D38E, D38M, D38W, Q24L, D30L, H34A, and / or D355L.
[0014] Contemplated subject matter also includes an aragonite composition formulated to bind to an immunoglobulin (Ig) protein, an anti-SARS-CoV2 antibody protein, or a SARS-CoV2 viral protein, the aragonite composition comprising a plurality of aragonite particle beads having an average particle size between 100 nm and 1 mm, the plurality of aragonite particle beads being functionalized with a moiety capable of binding to the immunoglobulin (Ig) protein, the anti-SARS-CoV2 antibody protein, and / or the SARS-CoV2 viral protein.
[0015] A further embodiment includes analyzing the patient sample for at least one antibody selected from an antibody targeting the virus or a protein specific for the virus, and in the absence of the antibody or in the presence of the viral protein, the method further includes administering a booster of the vaccine to the patient. The present invention also relates to the following: [Item 1] 1. A method for detecting the presence or absence of antibodies targeting Severe Acute Respiratory Syndrome (SARS-like coronavirus (SARS-CoV2) virus in a patient sample, comprising: incubating said patient sample solution with a recombinant SARS-CoV2 S protein, peptide, or variant thereof to form a SARS-CoV2 S treated sample solution; immobilizing recombinant human angiotensin-converting enzyme 2 (rhACE2) protein, peptide, or variants thereof onto a detection surface to form an ACE2-binding detection surface; incubating the SARS-CoV2 S-treated sample solution with the ACE2-binding detection surface to form a sample-treated ACE2-binding detection surface in solution; removing the solution from the sample-treated ACE2-binding detection surface to remove SARS-CoV2 S protein, peptide, or variant thereof that is not bound to the ACE2-binding detection surface; adding a labeled probe that binds to the SARS-CoV2 S protein, peptide, or variant thereof when bound to the immobilized rhACE2 protein, peptide, or variant thereof on the detection surface; and identifying or quantifying the labeled probes on the sample-treated ACE2-binding detection surface; The method, wherein detecting the labeled probe on the sample-treated ACE2-binding detection surface indicates the absence or reduction of anti-SARS-CoV2 S antibodies in the patient sample. [Item 2] 2. The method of claim 1, further comprising assaying the solution removed from the sample-treated ACE2 binding detection surface for the presence or absence of antibody-bound SARS-CoV2 S protein, peptide, or variants thereof. [Item 3] 2. The method of claim 1, wherein the recombinant SARS-CoV2 S protein, peptide, or variant thereof is selected from the group consisting of SARS-CoV2 S(R683A R685) trimer protein, SARS-CoV2 S(N501Y) protein, or SARS-CoV2 S(L452R) protein. [Item 4] 2. The method of claim 1, wherein the SARS-CoV2 S protein comprises a detectable label. [Item 5] 5. The method according to item 4, wherein the detection label is a histidine tag or an N-hydroxysuccinimide ester (NHS-ester) tag. [Item 6] 2. The method of claim 1, wherein the patient sample is saliva, nasal mucosa, or serum. [Item 7] 1. A method of inducing immunity against Severe Acute Respiratory Syndrome (SARS-like coronavirus (SARS-CoV2) virus in a mucosal tissue of a patient, the method comprising: administering a vaccine composition to said patient by delivery to the nasal mucosa, oral mucosa, and / or gastrointestinal mucosa. [Item 8] 8. The method of claim 7, further comprising co-administering the vaccine by injection into the patient's blood supply, wherein injection comprises an intramuscular (IM) injection, an intravenous (IV) injection, and / or a subcutaneous injection. [Item 9] moreover: 9. The method of claim 7 or 8, comprising obtaining a saliva sample from the patient at a period after administration of the vaccine. [Item 10] 10. The method of claim 9, wherein the saliva sample is preserved in a stabilizing solution comprising glutaraldehyde, sodium benzoate, citric acid, propyl gallate, EDTA, zinc, actin, chitosan, parabens, sodium azide, or any combination thereof. [Item 11] Item 11. The method according to item 10, wherein the stabilizing solution comprises 0.10 to 2.0 weight / volume % (w / v) glutaraldehyde, 0.10 to 1.0% w / v sodium benzoate, and / or 0.025 to 0.20% w / v citric acid. [Item 12] 12. The method according to claim 10 or 11, wherein the stabilizing solution further comprises aragonite particle beads having an average particle size of 100 nm to 1 mm. [Item 13] 12. The method of claim 11, wherein the aragonite particle beads are capable of binding to immunoglobulin (Ig) proteins. [Item 14] 13. The method of claim 12, wherein the aragonite particle beads are capable of binding to anti-SARS-CoV2 antibodies. [Item 15] 14. The method of claim 13, wherein the aragonite particle beads are bound to a recombinant ACE2 protein or a recombinant ACE2 alpha helix protein. [Item 16] 16. The method according to any one of items 9 to 15, further comprising analyzing the saliva sample for at least one analyte selected from an antibody targeting the virus or a protein specific for the virus. [Item 17] 17. The method of claim 16, further comprising administering a booster vaccine to the patient. [Item 18] 1. An aragonite composition formulated to bind to an immunoglobulin (Ig) protein or a SARS-CoV2 viral protein, comprising: A plurality of aragonite particle beads having an average particle size of 100 nm to 1 mm, The composition, wherein the plurality of aragonite particle beads are functionalized with a moiety selected from an Ig binding protein or a SARS-CoV2 virus binding protein. [Item 19] 19. The composition of claim 18, wherein the SARS-CoV2 virus-binding protein comprises a recombinant ACE2 protein. [Item 20] 20. The composition of claim 19, wherein the recombinant ACE2 protein has at least 85% sequence identity to SEQ ID NO:1. [Item 21] 20. The composition of claim 19, wherein the recombinant ACE2 protein comprises the primary sequence of SEQ ID NO:2. [Item 22] 22. The composition of claim 21, wherein the recombinant ACE2 protein comprises at least one mutation selected from T27F, T27W, T27Y, D30E, H34E, H34F, H34K, H34M, H34W, H34Y, D38E, D38M, D38W, Q24L, D30L, H34A and D355L. [Item 23] 23. The composition of any one of items 18 to 22, wherein the Ig is an anti-SARS-CoV2 antibody. [Item 24] 1. A composition for determining the need for a booster vaccination dose in a medical assistant and / or at a location remote from a medical facility, comprising: a. a saliva sample from the patient at said location; b. a saliva sample collection container, optionally containing a stabilizing solution comprising glutaraldehyde, sodium benzoate, citric acid, propyl gallate, EDTA, zinc, actin, chitosan, parabens, sodium azide, or any combination thereof; c. at least one dose of a vaccine against the SARS-COV-2 virus for administration by nasal inhalation, oral inhalation, or oral ingestion; The saliva sample is placed in the sample collection container and sent to a medical facility for analysis of mucosal antibodies by the assay described in item 1, the absence of mucosal antibodies indicating the need for a boosting dose of the vaccine. [Item 25] 25. The composition according to item 24, wherein the sample collection container contains a stabilizing solution comprising 0.10-2.0% weight / volume (w / v) glutaraldehyde, 0.10-1.0% w / v sodium benzoate, and / or 0.025-0.20% w / v citric acid. [Item 26] 25. The composition according to item 24, wherein the sample remains in the stabilizing solution for 1 to 48 hours. [Item 27] 25. The composition of claim 24, wherein the patient received at least one dose of a vaccine against SARS-CoV2 virus at least one week prior to producing the saliva sample. [Item 28] 25. The composition of item 24, wherein the oral vaccine comprises a replication-deficient adenoviral vector comprising: (a) a deletion in the E2b region; and (b) a nucleic acid sequence encoding two or more viral antigens, wherein the viral antigens comprise SARS-COV-2 S protein and SARS-COV-2 nucleocapsid protein.
[0016] Various objects, features, aspects and advantages of the present disclosure will become more apparent from the following detailed description of preferred embodiments, along with the accompanying drawings. [Brief description of the drawings]
[0017] [Figure 1A] 1 is a graph of an exemplary antibody neutralization assay of serum samples assayed with SARS-CoV2 S protein trimer at 2.971 nM and 1.4855 nM, according to an embodiment of the present disclosure. [Figure 1B] 1B is a graph of percent inhibition corresponding to the exemplary antibody neutralization assay of FIG. 1A, in accordance with an embodiment of the present disclosure. [Diagram 2] FIG. 1 shows the effect of 191V serum on SARS-CoV2 S protein trimer binding to ACE2 as measured by absorbance at A450, according to embodiments of the present disclosure. [Diagram 3] 1 is a graph showing percent inhibition of binding to ACE2 using plasma (114-P) and saliva (114-S) from patient 114 according to an embodiment of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] Contemplated subject matter includes compositions and methods for assaying for the presence or absence of neutralizing antibodies (e.g., anti-SARS-CoV2 antibodies) in a patient sample (e.g., saliva, nasal mucosa, gastrointestinal mucosa, or serum), and / or the isotype of any antibodies. The antibody status in a patient sample can be used to assess the need for additional vaccine doses (e.g., booster doses / shots).
[0019] Contemplated subject matter includes methods for administering the vaccine to a patient by two or more routes of administration to induce both local and systemic immune responses to the vaccine. The virus uses the S protein to enter host cells through interaction of the S receptor binding domain (S RBD) with angiotensin-converting enzyme 2 (ACE2), an enzyme that is widely expressed on various cell types in the nose, mouth, intestine, and lungs as well as other organs, and importantly, on alveolar epithelial cells in the lungs where infection is primarily expressed.
[0020] In addition to the viral epitopes presented in the vaccine, the route of administration of the vaccine and the regimen for administering additional (i.e., booster) doses of the vaccine can also influence whether a patient's immune response is sufficiently robust to establish protection.
[0021] For emerging viruses such as Severe Acute Respiratory Syndrome (SARS)-like coronavirus (SARS-CoV2), the duration of immunity (both humoral and cell-mediated) in patients who have recovered from SARS-CoV2 infection is not yet fully known, and furthermore, vaccine protocols have yet to be tested across various populations. Given the current SARS-CoV2 pandemic and the high rate of transmission of the SARS-CoV2 virus, there is a need for robust vaccination protocols and effective tests for the virus and / or immunity to the virus (e.g., the presence of neutralizing anti-SARS-CoV2 antibodies).
[0022] Vaccine administration. The contemplated methods disclosed herein for inducing immunity in patients include administering the vaccine at least by oral administration, preferably by oral administration and by injection into the blood supply. Many vaccines are given via the intramuscular (IM) route to optimize immunogenicity and induce systemic immunity with direct delivery of the vaccine into the intramuscular blood supply. IM administration is typically preferred over subcutaneous (SC) injection, which is more likely to have adverse reactions at the injection site than IM injection.
[0023] In addition to IM injection, it has been reported that induction of mucosal immunity is essential to prevent human-to-human transmission of pathogenic microorganisms and limit their proliferation in mucosal tissues. Furthermore, for protective immunity against mucosal pathogens (e.g., SARS coronavirus), instead of the more common approach of tolerance to maintain mucosal homeostasis, immune activation in mucosal tissues allows for enhanced mucosal immune responses and better local protection. For example, nasal vaccination (delivery of vaccines via nasal administration) induces both mucosal and systemic immunity. See, for example, Fujikuyama et al., 2012, Expert Rev Vaccines, 11:367-379 and Birkhoff et al., 2009, Indian J.Pharm.Sci., 71:729-731.
[0024] To induce both mucosal and systemic immunity in a patient, embodiments of the present disclosure include providing the vaccine to a patient by administration to at least the patient's nasal, oral, and / or gastrointestinal mucosa. In some embodiments, the route of administration includes administering the vaccine to the patient's nasal, oral, and / or gastrointestinal mucosa together with injection into the blood supply (e.g., intramuscular (IM), intravenous (IV), or subcutaneous (SC)). As used herein, oral administration of a vaccine composition includes nasal injection, nasal inhalation, oral ingestion, and administration to the gastrointestinal mucosa (e.g., inhalation, ingestion, injection). Preferably, the route of administration of the vaccine includes oral administration selected from delivery to the gastrointestinal mucosa, nasal injection, nasal inhalation, oral ingestion, or oral inhalation together with administration by intramuscular (IM) injection.
[0025] In particular, the vaccine administered to induce immunity in the mucosal tissues of the patient is a SARS-CoV2 vaccine. In an exemplary embodiment, the SARS-CoV2 vaccine (e.g., an adenoviral construct) comprises a soluble ACE2 protein bound to an immunoglobulin Fc portion to form an ACE2-Fc hybrid construct, which may also include a J-chain portion, as disclosed in US 16 / 880,804 and US 63 / 016,048, the entire contents of both of which are incorporated herein by reference. In another exemplary embodiment, the SARS-CoV2 vaccine (e.g., an adenoviral construct) comprises a mutant of a recombinant soluble ACE2 protein (e.g., SEQ ID NO: 2), which has at least one mutated amino acid residue (e.g., by substitution) that confers an increased binding affinity of the ACE2 protein to the RBD protein domain of the SARS-CoV2 spike protein, as disclosed in US 63 / 022,146, the entire contents of which are incorporated herein by reference. In another exemplary embodiment, the SARS-CoV2 vaccine (e.g., adenoviral construct) comprises a CoV2 nucleocapsid protein or a CoV2 spike protein fused to an endosomal targeting sequence (N-ETSD), as disclosed in U.S. Patent Application No. 16 / 883,263 and U.S. Patent No. 63 / 009,960, the entire contents of both of which are incorporated herein by reference. Additionally or alternatively, the SARS-CoV2 vaccine comprises modified yeast cells (e.g., Saccharomyces cerevisiae) genetically engineered to express coronavirus spike protein on the yeast cell surface, as disclosed in U.S. Patent Application No. 63 / 010,010, whereby the yeast display cells stimulate B cells (e.g., humoral immunity).
[0026] In some embodiments, two or more vaccine compositions disclosed herein may be administered to a patient to induce immunity against SARS-CoV2. For example, a patient may be administered genetically modified yeast cells expressing the coronavirus spike protein as a single type of vaccine, or the genetically modified yeast cells may be administered together or simultaneously with one or more SARS-CoV2 adenovirus constructs disclosed herein.
[0027] Monitoring the Presence of Antibodies. The present disclosure includes monitoring or evaluating a patient's immune response to either an administered vaccine (e.g., orally and / or by injection into the blood supply as disclosed herein) or infection with a virus. In particular, compositions and methods are disclosed herein for evaluating the continued presence of antibodies in a patient's respiratory and digestive mucosa following infection with SARS-CoV2 or following inoculation against SARS-CoV2 by administration of a SARS coronavirus vaccine.
[0028] To assay samples from patients who have received a vaccine against a pathogenic infection (e.g., targeting SARS-CoV2) and / or have been infected with a virus (e.g., SARS-CoV2), the presence of antibodies against the pathogen can be performed using any one of a number of diagnostic tests. In some embodiments, the diagnostic test is a cell viability assay that allows for detection of antibodies in the presence of an antigen. An exemplary diagnostic test using a cell viability assay for anti-SARS-CoV2 antibody detection is disclosed in U.S. Patent No. 63 / 053,691, the entire contents of which are incorporated herein by reference. Cytological diagnostic assays rely on the expression of a target receptor for a given pathogen (e.g., ACE2 for SARS-CoV2 infection) on the surface of an immune effector cell line (e.g., killer T cells, natural killer cells, NK-92® cells and their derivatives, etc.) and the expression of a pathogen ligand (e.g., spike protein for SARS-CoV2 infection) on the surface of a surrogate cell line (e.g., HEK293 cells or SUP-B15 cells).
[0029] Further diagnostic tests using recombinant protein variants of the ACE2 protein (the human receptor targeted by the SARS-CoV2 spike protein) are disclosed in U.S. Patent Application No. 16 / 880,804, the entire contents of which are incorporated herein by reference.
[0030] In some preferred embodiments, recombinant human ACE2 (rhACE2) protein or peptide is immobilized on a detection surface. A patient sample is incubated with SARS-CoV2 spike (S) protein or peptide (e.g., recombinant SARS-CoV2 spike protein or peptide thereof), and the incubated S protein or peptide and sample are then exposed together to a detection surface with immobilized ACE2 protein or peptide. If the patient sample does not contain any neutralizing anti-SARS-CoV2 antibodies, the receptor binding domain (RBD) of the S protein is available to bind to the ACE2 protein on the detection surface, and the bound S protein is detected using a labeled probe against the S protein. Thus, the presence of neutralizing (e.g., inhibiting) anti-SARS-CoV2 antibodies in the patient sample inhibits the S protein or peptide from binding to ACE2 on the detection surface, thereby preventing detection of the S protein label. Thus, when the label is detected spectrophotometrically, the increase or presence of signal (color, fluorescence, luminescence) inversely correlates with the presence of neutralizing anti-SARS-CoV2 antibodies.
[0031] For rapid SARS-CoV2 antibody detection in patient samples, rhACE2 protein or peptides can be immobilized on the surface of aragonite particle beads, or alternatively, on a flat surface suitable for immobilizing protein reagents (e.g., polystyrene multi-well plates). The present disclosure includes kits and methods that use a suitable detection surface (e.g., aragonite particle beads or multi-well plates) pre-bound with rhACE2 protein, peptide, or variants thereof.
[0032] In addition to or instead of wild-type rhACE2 protein or peptide fragments, mutant ACE2 proteins or peptides can be immobilized on the detection surface to further characterize or confirm the binding ability of anti-SARS-CoV2 antibodies found in patient samples. In certain embodiments, the detection surface of an aragonite particle bead or a polystyrene plate is functionalized with a recombinant ACE2 protein having at least 85% sequence identity to SEQ ID NO: 1, a recombinant α-helical ACE2 protein of SEQ ID NO: 2, or a recombinant α-helical ACE2 protein having at least one mutation selected from T27F, T27W, T27Y, D30E, H34E, H34F, H34K, H34M, H34W, H34Y, D38E, D38M, D38W, Q24L, D30L, H34A, and / or D355L. In further embodiments, soluble ACE2 protein variants with enhanced binding affinity to the RBD of SARS-CoV2 S protein can be used to determine the binding affinity and / or competitive inhibition of any anti-SARS-CoV2 antibodies in patient samples. See, e.g., Chan et al., 2020, Science, 369:1261-1265, the entire contents of which are incorporated herein by reference.
[0033] Antibody testing in saliva samples. To more easily monitor patients for the presence of anti-pathogen antibodies, assaying saliva samples from patients may allow for rapid sample collection, increased patient participation, and allow patients to obtain their own samples and mail or transport the samples to a laboratory for testing. However, to assay saliva for the presence of neutralizing antibodies to SARS-CoV2, it may be necessary to stabilize proteins in saliva against degradation during transportation and storage after sample collection prior to testing.
[0034] Once the saliva sample is collected, the saliva is placed in a preservative solution to stabilize the components therein (e.g., anti-SARS CoV2 antibodies or viral spike proteins). Preservatives for biological samples are disclosed, for example, in Cunningham & al. (2018) report ("Effective Long-term Preservation of Biological Evidence," USDepartment of Justice grant # 2010-DN-BX-K193) and U.S. Patent No. 6,133,036 to Putcha et al. For example, a stabilizing preservative solution for a patient's saliva sample may include any one of glutaraldehyde, sodium benzoate, citric acid, propyl gallate, EDTA, zinc, actin, chitosan, parabens, sodium azide, and any combination thereof.
[0035] In certain embodiments, the saliva sample may be mixed with a stabilizing preservative solution of glutaraldehyde to achieve a final glutaraldehyde concentration of between 0.1% (w / v) and 2.0% (w / v), e.g., about 0.2% (w / v), about 0.3% (w / v), about 0.4% (w / v), about 0.5% (w / v), about 0.6% (w / v), about 0.7% (w / v), about 0.8% (w / v), about 1.0% (w / v), about 1.1% (w / v), about 1.2% (w / v), about 1.3% (w / v), about 1.4% (w / v), about 1.5% (w / v), about 1.6% (w / v), 1.7% (w / v), about 1.8% (w / v), or about 1.9% (w / v).
[0036] In additional or alternative embodiments, the saliva sample may be mixed with a stabilizing preservative solution of about 0.10% to about 1.00% sodium benzoate (weight / volume of sample) and / or about 0.025% to about 0.20% citric acid (weight / volume of sample). For example, the saliva sample may be mixed with 0.10%, 0.20%, 0.30%, 0.40%, 0.50%, 0.60%, 0.70%, 0.80%, 0.90%, or 1.00% w / v sodium benzoate. In further embodiments, the saliva sample contains at least 0.5 mg / mL (e.g., at least 0.6 mg / mL, at least 0.7 mg / mL, at least 0.8 mg / mL, at least 0.9 mg / mL, at least 1 mg / mL, at least 1.5 mg / mL, at least 2 mg / mL, at least 2.5 mg / mL, at least 3 mg / mL, at least 3.5 mg / mL, at least 4 mg / mL, at least 4.5 mg / mL, or even 5 mg / mL) of benzoic acid. and / or mixed with a stabilizing preservative solution of at least 0.2 mg / mL (e.g., at least 0.2 mg / mL, at least 0.25 mg / mL, at least 0.3 mg / mL, at least 0.35 mg / mL, at least 0.40 mg / mL, 0.50 mg / mL, at least 0.75 mg / mL, at least 1.0 mg / mL, at least 1.25 mg / mL, at least 1.5 mg / mL, at least 1.75 mg / mL, or even 2.0 mg / mL) citric acid. As used herein, "benzoic acid" is interchangeable with benzoate salts (e.g., sodium benzoate) and "citric acid" is interchangeable with citrate salts (e.g., sodium citrate).
[0037] The saliva sample containing the preservatives described above is stable to storage for at least 1 hour (e.g., at least 5 hours, at least 10 hours, at least 12 hours, at least 24 hours, at least 36 hours, or at least 48 hours) at a temperature between 15° C. and 40° C. Thus, disclosed herein is a method of storing a saliva sample for neutralizing antibody testing, comprising mixing the saliva sample with a stabilizing solution made from one or more of glutaraldehyde, sodium benzoate, citric acid, propyl gallate, EDTA, zinc, actin, chitosan, parabens, and / or sodium azide, and storing at 15° C. to 25° C. for at least 1 hour, up to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 36, or 48 hours. In some embodiments, the saliva sample is mixed with a glutaraldehyde concentration of 0.1% (w / v) to 2.0% (w / v) and the glutaraldehyde-saliva is stored at 15° C. to 25° C. In certain embodiments, the glutaraldehyde-saliva may further comprise citric acid and / or benzoic acid in concentrations disclosed herein.
[0038] Aragonite: In some embodiments, any antibody protein or any specific antibody protein can be captured from a saliva sample using ovo-shaped aragonite particles. For example, the saliva preservation solutions of glutaraldehyde, sodium benzoate and citric acid, propyl gallate, EDTA, zinc, actin, chitosan, parabens, sodium azide, and any combination thereof disclosed herein can also include ovo-shaped aragonite (calcium carbonate, CaCO3) particles. The use of aragonite particles for binding to proteins is disclosed, for example, in U.S. Patent Application Nos. 16 / 858,548 and PCT / US20 / 29949, the entire contents of both of which are incorporated herein by reference. Thus, aragonite particles can be added to capture (e.g., bind to) any antibodies present in a saliva sample or modified to specifically capture antibodies against a particular antigen. For example, aragonite can be functionalized with moieties capable of binding to immunoglobulin (Ig) proteins. Preferably, the Ig protein is an immunoglobulin A (IgA), immunoglobulin G (IgG), or immunoglobulin E (IgE) protein. More preferably, the aragonite is functionalized to bind to an IgA protein. Most preferably, the aragonite particles are functionalized with a moiety capable of binding to a specific antibody. For example, the aragonite particles can be coupled to a moiety specific for an anti-SARS-CoV2 antibody. Preferably, the aragonite particles are coupled to a recombinant ACE2 protein, for example as disclosed in the above-mentioned US patent application Ser. No. 16 / 880,804. In a typical embodiment, the aragonite particles are coupled to a recombinant human ACE2 protein having at least 85%, at least 90%, or at least 95% sequence identity to SEQ ID NO:1.
[0039] In additional or alternative embodiments, the aragonite particles are functionalized (e.g., conjugated) to recombinant soluble ACE2 protein (e.g., SEQ ID NO: 2). For more efficient capture or binding of anti-SARS-CoV2 antibodies or spike protein of SARS CoV2, recombinant soluble ACE2 can be mutated to form ACE2 mutants with higher binding affinity to SARS-CoV2 spike protein (e.g., RBD domain of spike protein). These ACE2 mutants of recombinant soluble ACE2 protein include T27F, T27W, T27Y, D30E, H34E, H34F, H34K, H34M, H34W, H34Y, D38E, D38M, D38W, Q24L, D30L, H34A, and / or D355L.
[0040] As used herein, the term "functionalized" refers to the coupling or binding of a moiety to an aragonite particle, thereby imparting any functionality of the attached moiety to the aragonite particle. For example, the aragonite particle may be functionalized with a protein moiety. Methods for preparing and using aragonite particle beads are disclosed in U.S. Patent Application No. 16 / 858,548 and PCT / US20 / 29949. In some embodiments, the aragonite composition comprises a plurality of aragonite particle beads. Preferably, the plurality of aragonite particle beads has an average particle size of 100 nm to 1 mm.
[0041] In some embodiments, the protein moiety is directly attached to the native untreated surface of the aragonite particle. The aragonite particle has an amino acid content of 2-3%, including aspartic acid and glutamic acid, which render the aragonite surface hydrophilic. Thus, in some embodiments, the protein moiety may be directly attached to the surface of the aragonite particle.
[0042] In an alternative embodiment, the aragonite particle surface can be treated to modify the binding surface. For example, as disclosed in US Patent Application No. 16 / 858,548 and PCT / US20 / 29949, treatment with stearic acid (i.e., octadecanoic acid) provides a hydrophobic surface. For protein loading, treatment of aragonite with phosphoric acid forms a lamellar structure. Further conjugation techniques for binding reactive groups to the amino acid surface of aragonite are known in the art, as disclosed, for example, in Bioconjugate Techniques, Third Edition, Greg T. Hermanson, Academic Press, 2013.
[0043] Monitoring of Vaccine Protocols: Patients who do not demonstrate sufficient titers (e.g., presence) of neutralizing antibodies in their saliva can be sent oral doses of the respective vaccine (e.g., the SARS-CoV2 vaccine disclosed herein). Patients inhale or ingest these vaccine doses, and then two weeks later, send another saliva sample, prepared and stored in the same manner as above, to a testing facility to confirm that the oral vaccine dose has restored their anti-SARS-CoV2 antibody (e.g., IgA) titers.
[0044] Thus, in a further embodiment, a kit for collecting a saliva sample from a patient includes a collection container with a saliva preservative solution as disclosed herein. For example, the kit includes a collection container with a solution of any one or combination of glutaraldehyde, sodium benzoate and / or citric acid, propyl gallate, EDTA, zinc, actin, chitosan, parabens, and sodium azide. The kit may also include adhesive packaging and / or mailing supplies to secure the collection container with the saliva sample for shipping or mailing. In some embodiments, the kit may also include at least one dose of a vaccine for oral administration.
[0045] Ranges of values recited herein are merely intended as shorthand for referring individually to each separate value falling within the range, and unless otherwise indicated herein, each individual value is incorporated herein as if it were individually recited herein.
[0046] As used throughout this specification and the claims that follow, "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Also, "in" includes "in" and "on," unless the context clearly dictates otherwise. Also, as used herein, unless the context clearly dictates otherwise, "coupled to" includes both direct coupling (wherein the two elements that are coupled to each other are in contact with each other) and indirect coupling (wherein at least one additional element is located between the two elements). Thus, "coupled to" and "coupled with" are synonymous.
[0047] "Comprise" and "comprising" should be construed as referring to elements, components, or steps in a non-exclusive manner, indicating that the referenced element, component, or step may be present, utilized, or combined with other elements, components, or steps not expressly referenced. If the specification or claims refer to at least one selected from the group consisting of A, B, C... and N, the sentence should be construed as requiring only one element from the group, and not A+N, or B+N, etc. EXAMPLES
[0048] Example 1. The advantageous features of the compositions and methods described herein are further illustrated by (but not limited to) the following examples. SUP-B15 cells are transfected with a construct comprising a CMV promoter operably linked to a sequence encoding the SARS CoV-2 spike protein. The spike is expressed and naturally localizes to the extracellular face of the cell membrane. The transfected SUP-B15 cells are seeded in a 6-well dish, allowed to attach, and grown to approximately 60% confluence. Three wells of this 6-well dish are incubated with haNK cells transfected to express a CAR with the ACE2 extracellular domain, while the other three are incubated with the same haNK cells in the presence of convalescent serum from a patient who recently recovered from COVID19. After 1 hour of incubation at 37°C and 5% CO2, viability is measured. The three wells with convalescent serum have an average cell viability of 90%, while the three wells without convalescent serum show an average cell viability of 50%.
[0049] Without wishing to be bound by theory, one advantage of the diagnostic compositions and methods disclosed herein over existing surrogate neutralizing antibody diagnostics is that antibodies found in patient sera may alter the ACE-2 / Spike interaction by binding elsewhere on Spike (rather than direct Spike-RBD / ACE-2 inhibition). In the presence of haNK® cells, antibodies that neutralize by inhibiting ADCC would also be recognizable by this method.
[0050] Example 2. Saliva samples are collected from one or more patients and stored in 1.5 mL snap-cap polystyrene tubes, each labeled with a mark indicating the identity of the patient from whom the sample was collected. To each tube of saliva sample, an approximately equal volume of solution is added, the solution being a solution of 2.0% weight / volume (w / v) glutaraldehyde with 1 mg / mL sodium benzoate solution. The glutaraldehyde and sodium benzoate solutions added to the saliva samples result in a solution in each tube having a final concentration of about 1.0% (w / v) glutaraldehyde / 0.5 mg / mL sodium benzoate. The tubes are appropriately packaged for shipment and transported to a testing facility. The approximate time from sample collection to the time the sample is opened at the facility for testing is 48 hours or less, typically about 24 hours or less. For example, the time between sample collection and opening of the sample at the testing site can range from about 1 minute to 48 hours or less, preferably 1 minute to about 36 hours. Typically, the time between sample collection and release of the sample at the test site can range from about 1 minute to about 30 hours, from 1 minute to about 30 hours, from 1 minute to about 30 hours, from 1 minute to about 30 hours, from 1 minute to about 24 hours, from 1 minute to about 20 hours, from 1 minute to about 19 hours, from 1 minute to about 18 hours, from 1 minute to about 18 hours, from 1 minute to about 18 hours, from 1 minute to about 18 hours, from 1 minute to about 18 hours, from 1 minute to about 18 hours, from 1 minute to about 18 hours, from 1 minute to about 18 hours, from 1 minute to about 18 hours, from 1 minute to about 18 hours, from 1 minute to about 18 hours, from 1 minute to about 18 hours, from 1 minute to about 18 hours, from 1 minute to about 18 hours, from 1 minute to about 30 hours (e.g., 18 hours to 30 hours or therebetween). During the approximately 24 hour period, the sample never reaches a temperature colder than about 15° C. (e.g., between 18 and 30 hours or thereabout), never gets hotter than about 40° C., and averages about 25° C. over the approximately 24 hour period (e.g., between 18 and 30 hours or thereabout). Thus, the sample may be at a temperature of about 15° C., 16° C., 17° C., 18° C., 19° C., 20° C., 21° C., 22° C., 23° C., 24° C., 25° C., 26° C., 27° C., 28° C., 29° C., 30° C., 31° C., 32° C., 33° C., 34° C., 35° C., 36° C., 37° C., 38° C., 39° C., or 40° C.
[0051] At the testing facility, a technician opens each tube and extracts the contents with a sterile pipette. The solution is dialyzed to remove glutaraldehyde and benzoate. The dialyzed sample is then mixed with a peptide that mimics the SARS-CoV2 spike protein receptor-binding domain (RBD) and incubated at room temperature for 30 minutes.
[0052] The peptide is conjugated to horseradish peroxidase (HRP). The RBD peptide / sample (antibody) mixture is then added to the wells of a multi-well polystyrene plate, the inner surface of which has been coated with recombinant human ACE2 (rhACE2), and incubated for 30 minutes at room temperature. At the end of the incubation, the wells are washed three times with room temperature PBS, and 3,3',5,5'-tetramethylbenzidine (TMB) is added to each well. Wells that received samples without neutralizing antibodies turn dark blue, while wells that received samples with neutralizing antibodies remain clear. The darkness of the TMB indicates the OD 450 1A, 1B, 2, and 3, the raw spectrophotometric data corresponds to OD450 (or A450), and the presence of neutralizing antibodies correlates with inhibition of binding to coated rhACE2, which results in a decrease in OD450.
[0053] Example 3. Exemplary assay method for neutralizing anti-SARS-CoV2 S antibodies in patient samples. Coat a microplate (e.g., a Nunc MaxiSorp ELISA plate with 100 μl / well) with antigen. Dilute human ACE2-hFC protein to 0.5 ug / mL (ImmunityBio, Inc. 2.5 mg / mL) (approximately 4.5455 nM, DF=1:5,200) in coating buffer (BioLegend catalog number 421701, diluted with water for injection (WFI)). Coat each well of the microplate with the diluted ACE2-hFC protein. Cover the microplate with sticky plastic and incubate at 4° C. overnight.
[0054] Remove the coating solution from each well and wash three times (3x) with 200-250 μl PBS / well. Remove the solution or wash by flicking the plate over a sink. Remove any remaining droplets by tapping the plate on a paper towel.
[0055] The coated wells are blocked by adding 200 μl / well of blocking buffer (2% non-fat dry milk in DPBS).
[0056] The blocked wells are then covered with sticky plastic and incubated for 1-2 hours at 37°C. The blocking buffer is removed by flicking the plate over a sink. The wells are washed 3 times with 200-250uL 0.05% Tween20 / PBS.
[0057] A patient sample (e.g., saliva or serum) is incubated with a SARS-CoV2 S protein, peptide, or variant thereof (e.g., SARS-CoV2 S(R683A R685) trimeric protein, SARS-CoV2 S(N501Y) protein, or SARS-CoV2 S(L452R) protein).
[0058] Prepare "2x" sample (e.g., saliva or serum) dilutions in 2% NF milk / PBS (60uL volume). DF range (mouse serum) = 250-250,000. For example, dilute SARS-CoV-2 S protein (R683A, R685A), active trimer, His-tagged, "S-trimer" (Acro Biosystems, SPN-C52H9; stock @ 205ug / mL (1.4855uM)) in blocking buffer as shown in Table 1 below.
[0059] [Table 1]
[0060] Add 60 uL of diluted sample, 60 uL of the appropriate S-trimer dilution per well of a 1.2 mL 96-well plate according to the layout below. Mix by pipetting. Cover the plate with sticky plastic and incubate at 37 °C for 30 minutes.
[0061] After blocking and subsequent washing of the hACE2-hFC coated wells, the sample and S-trimer mixture are incubated with the antigen (ACE2) coated plate. For example, 100 uL / well of sample and S-trimer mixture are added and incubated at 37°C for 30 minutes to 2 hours. After this incubation, the wells are washed up to four times (4x) with 200-250 uL 0.05% Tween20 / PBS. The wells are then incubated with a detection reagent to determine the amount of S-trimer bound to the wells. In this example, the S-trimer is His-tagged and can be detected using an anti-HIS HRP conjugated antibody (BioLegend #_652504, @0.5 mg / mL; recommended use at 0.01-1 ug / mL). For detection with TMB (3,3',5,5'-tetramethylbenzidine), 100 μl of diluted conjugated secondary antibody solution is added per well. Cover plate with adhesive plastic cover and incubate for 1 hour at 37°C. Wash plate 4 times with 200-250μL / well 0.05% Tween20 / PBS. Mix TMB substrate (Pierce TMB Substrate Kit Cat#34021) 1:1. Add 100uL of TMB solution to each well. Incubate up to 30 minutes at room temperature in the dark. Stop reaction by adding an equal volume (100uL) of stop solution (Thermo #N600). Read optical density at 450nm within 30 minutes of stopping using an ELISA plate reader.
[0062] All methods described herein may be performed in any suitable order unless otherwise indicated herein or clearly contradicted by context. Any and all examples provided in connection with specific embodiments herein, or the use of exemplary language (e.g., "etc."), are intended merely to further clarify the invention and do not limit the scope of the invention as otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
[0063] It will be apparent to those skilled in the art that many more modifications besides those already described are possible without departing from the inventive concepts herein. Accordingly, the disclosure is not to be limited except as by the appended claims. Moreover, in interpreting both the specification and the claims, all terms should be interpreted in the broadest manner consistent with the context.
Claims
1. 1. A method for detecting the presence or absence of antibodies targeting Severe Acute Respiratory Syndrome (SARS)-like coronavirus (SARS-CoV2) virus in a patient sample, comprising: incubating said patient sample solution with a recombinant SARS-CoV2 S protein, peptide, or variant thereof selected from SARS-CoV2 S(R683A R685) trimer protein, SARS-CoV2 S(N501Y) protein, or SARS-CoV2 S(L452R) protein to form a SARS-CoV2 S-treated sample solution; immobilizing a recombinant human angiotensin-converting enzyme 2 (rhACE2) protein, peptide, or variants thereof onto a detection surface to form an ACE2-bound detection surface; incubating the SARS-CoV2 S-treated sample solution with the ACE2-binding detection surface to form a sample-treated ACE2-binding detection surface in solution; removing the solution from the sample-treated ACE2-binding detection surface to remove SARS-CoV2 S protein, peptide, or variant thereof that is not bound to the ACE2-binding detection surface; adding a labeled probe that binds to the SARS-CoV2 S protein, peptide, or variant thereof when bound to the immobilized rhACE2 protein, peptide, or variant thereof on the detection surface; identifying or quantifying the labeled probes on the sample-treated ACE2-binding detection surface; Including, Detecting the labeled probe on the sample treated ACE2-bound detection surface indicates the absence or reduction of anti-SARS-CoV2 S antibodies in the patient sample.
2. 10. The method of claim 1, further comprising assaying the solution removed from the sample processing ACE2-binding detection surface for the presence or absence of antibody-bound SARS-CoV2 S protein, peptide, or variants thereof.
3. 2. The method of claim 1, wherein the SARS-CoV2 S protein comprises a detectable label.
4. The method of claim 3, wherein the detection label is a histidine tag or an N-hydroxysuccinimide ester (NHS-ester) tag.
5. The method of claim 1 , wherein the patient sample is saliva, nasal mucosa, or serum.
6. 1. A kit for determining the need for a booster vaccination dose at a medical assistant and / or at a location remote from a medical facility, comprising: a container for collecting a patient's saliva sample; and At least one dose of a vaccine against the SARS-COV-2 virus formulated for administration by nasal inhalation, oral inhalation, or oral ingestion. Including, The saliva sample is placed in the container and sent to a medical facility for analysis of mucosal antibodies by the method of claim 1, the absence of mucosal antibodies indicating the need for a booster dose of the vaccine.
7. 7. The kit of claim 6, wherein the container contains a stabilizing solution comprising 0.10-2.0% weight / volume (w / v) glutaraldehyde, 0.10-1.0% w / v sodium benzoate, and / or 0.025-0.20% w / v citric acid.
8. The kit of claim 7, wherein the saliva sample remains in the stabilizing solution for 1 to 48 hours.
9. 7. The kit of claim 6, wherein the patient received at least one dose of a vaccine against SARS-CoV2 virus at least one week prior to producing the saliva sample.
10. 7. The kit of claim 6, wherein the vaccine comprises a replication-deficient adenoviral vector comprising (a) a deletion in the E2b region and (b) a nucleic acid sequence encoding two or more viral antigens, wherein the viral antigens comprise a SARS-COV-2 S protein and a SARS-COV-2 nucleocapsid protein.
Citation Information
Patent Citations
Methods and reagents for diagnosing SARS-cov-2 infection
JP2021167805A
